title: [Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure].
abstract: Sevelamer is a recent phosphate binder that is mineral-free, and represents a great advance in the treatment of hyperphosphatemia in patients with hypercalcemia and/or gastric intolerance to calcium-based phosphate binders. The communications about the experience with the use of sevelamer in patients non-yet in dialysis is scanty. The aim of our study is to investigate retrospectively the gastrointestinal tolerance of sevelamer, their efficacy as phosphate binder and other parameters in a group of 89 patients with chronic renal failure in predialysis. We have analysed the effects of sevelamer at baseline and after 1, 3 and 6 months on the following data and parameters: calcium, phosphate, intact PTH, venous bicarbonate, urea, creatinine, creatinine clearance, side-effects, number of patients that were discontinued, and co-treatment during the study period with phosphate-based binders, calcitriol, lipid-lowering drugs and sodium bicarbonate.
  
  
  RESULTS
  19 patients (21.3%) refused to continue with sevelamer at the first month (16 patients had digestive intolerance and 3 several symptoms). Serum phosphate fell at 3 months (5 +/- 0.8 mg/dl basal vs 4.8 +/- 0.7 mg/dl, p = 0.02) and 6 months (5 +/- 0.8 mg/dl basal vs 4.7 +/- 0.9 mg/dl, p = 0.07). Serum calcium fell at 6 months (9.8 +/- 0.7 mg/dl basal vs 9.4 +/- 0.6 mg/dl, p = 0.03). Venous bicarbonate and iPTH were unchanged, but the quantity of sodium bicarbonate administered increased significantly. Blood cholesterol fell at 1 months (193 +/- 49 mg/dl basal vs 173 +/- 52 mg/dl, p = 0.001) and 3 months (205 +/- 49 mg/dl basal vs 170 +/- 49 mg/dl, p = 0.004), in spite of a significant reduction of the dose of statins.
  
  
  CONCLUSIONS
  Sevelamer is an effective phosphate binder in predialysis patients and also reduces significantly the serum cholesterol, improving the blood lipid profile. The levels of venous bicarbonate remained unchanged, at expenses of an increment in the dose of sodium bicarbonate supplementation.
authors.affiliation: Servicio de Nefrología, Hospital Universitario Virgen del Rocío, Sevilla.
authors.forename: M
authors.initials: M
authors.lastname: Suñer
authors.forename: A
authors.initials: A
authors.lastname: Guerrero
authors.forename: R
authors.initials: R
authors.lastname: Montes
authors.forename: M
authors.initials: M
authors.lastname: Rivera
authors.forename: A
authors.initials: A
authors.lastname: Ruiz
authors.forename: M
authors.initials: M
authors.lastname: Martínez-García
authors.forename: M A
authors.initials: MA
authors.lastname: Pérez-Valdivia
authors.forename: J
authors.initials: J
authors.lastname: Mateos
mesh_terms: D000136:Acid-Base Equilibrium / Q000187:drug effects; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001639:Bicarbonates / Q000097:blood; D002118:Calcium; D002614:Chelating Agents / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004852:Epoxy Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy; D006937:Hypercholesterolemia / Q000097:blood; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010342:Patient Acceptance of Health Care; D010710:Phosphates / Q000097:blood*; D011073:Polyamines; D011095:Polyethylenes / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D000069603:Sevelamer
chemical_list: D001639:Bicarbonates; D002614:Chelating Agents; D004852:Epoxy Compounds; D000960:Hypolipidemic Agents; D010281:Parathyroid Hormone; D010710:Phosphates; D011073:Polyamines; D011095:Polyethylenes; D000069603:Sevelamer; D002118:Calcium